ValuEngine downgraded shares of Quotient (NASDAQ:QTNT) from a buy rating to a hold rating in a report published on Wednesday morning.
Several other analysts have also weighed in on QTNT. BidaskClub lowered Quotient from a hold rating to a sell rating in a report on Wednesday, November 28th. Zacks Investment Research lowered Quotient from a hold rating to a sell rating in a report on Friday, November 9th.
NASDAQ:QTNT opened at $6.91 on Wednesday. Quotient has a one year low of $2.78 and a one year high of $9.02. The stock has a market capitalization of $375.43 million, a P/E ratio of -3.42 and a beta of 0.50.
Quotient (NASDAQ:QTNT) last announced its quarterly earnings data on Monday, November 5th. The company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.17). The company had revenue of $6.25 million during the quarter, compared to analysts’ expectations of $5.80 million. Analysts forecast that Quotient will post -1.92 EPS for the current year.
Institutional investors have recently made changes to their positions in the stock. Trexquant Investment LP bought a new stake in Quotient in the second quarter valued at about $102,000. PEAK6 Investments LLC bought a new stake in Quotient in the third quarter valued at about $109,000. Bank of America Corp DE increased its holdings in Quotient by 539.0% in the second quarter. Bank of America Corp DE now owns 16,768 shares of the company’s stock valued at $135,000 after buying an additional 14,144 shares during the last quarter. Cim Investment Mangement Inc. bought a new position in shares of Quotient during the second quarter valued at approximately $407,000. Finally, Quantum Capital Management bought a new position in shares of Quotient during the second quarter valued at approximately $429,000. 60.78% of the stock is owned by hedge funds and other institutional investors.
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Featured Article: Analyst Ratings
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.